Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Freeline Therapeutics Holdings plc Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Investor presentation by the Company",
"Investor presentation by the Company"
10/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease Robust increases of up to 700-fold over baseline in plasma GCase enzyme activity in first two patients treated with FLT201 Normalization of leukocyte GCase in both patients demonstrates cellular uptake from plasma FLT201 has been well tolerated, with no serious adverse events Company to host conference call today at 8 a.m. ET"
08/15/2023 6-K Quarterly results
Docs: "Freeline Reports Second Quarter 2023 Financial Results and Business Highlights Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical data in third quarter of 2023 Extending impact of its novel GCase variant with research program for GBA1-linked Parkinson’s disease Management to host conference call at 8:00 a.m. ET today"
05/31/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Notice of Annual General Meeting",
"Form of Proxy for Holders of Ordinary Shares",
"Freeline Therapeutics Holdings plc Annual Report and Accounts for the fiscal year ended December 31, 2022",
"Depositary's Notice of Annual General Meeting",
"2023 Voting Instructions for Holders of American Depositary Shares"
05/12/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Freeline Completes ADS Ratio Change"
04/21/2023 6-K Quarterly results
04/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Freeline Reports Full Year 2022 Financial Results and Provides Corporate Update Prioritizing development of FLT201, a potential first- and best-in-class gene therapy for most common type of Gaucher disease Initial clinical data on FLT201 expected in Q3 2023 Restructuring organization and pausing development of FLT190 to extend cash runway into Q2 2024 Appointed CFO Paul Schneider to Board of Directors Management to host conference call today at 8 a.m. ET"
02/10/2023 6-K Quarterly results
11/29/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Freeline Receives Approval to Transfer to Nasdaq Capital Market"
11/15/2022 6-K Quarterly results
Docs: "6-K",
"Freeline Reports Third Quarter 2022 Financial Results and Corporate Update Entered into definitive agreement to sell CMC-focused German subsidiary and related IP for $25 million, while retaining rights to AAVS3 capsid and maintaining access to capabilities and technologies Streamlining organization and extending cash runway into 2024 Prioritizing development of FLT201 in Gaucher disease and FLT190 in Fabry disease; ceasing investment in further development of FLT180a in hemophilia B Updated data from first cohort of MARVEL-1 trial show FLT190 continues to be well-tolerated with sustained a-Gal A enzyme increases up to three years after dosing"
10/04/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease"
08/26/2022 6-K Quarterly results
08/09/2022 6-K Quarterly results
07/11/2022 6-K Quarterly results
06/30/2022 6-K Quarterly results
06/14/2022 6-K Quarterly results
06/03/2022 6-K Quarterly results
05/23/2022 6-K Quarterly results
05/10/2022 6-K Quarterly results
04/19/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Freeline Appoints Paul Schneider as Chief Financial Officer"
03/31/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Freeline Reports Full Year 2021 Financial Results and Business Highlights Phase 1/2 programs on track in Hemophilia B and Gaucher disease and accelerated in Fabry disease Extended financial runway and streamlined organization support Company"
03/24/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Freeline Announces Updated Development Plan and Timelines for FLT190 for People with Fabry Disease Company to progress to second dose cohort in the MARVEL-1study immediately, with first patient dosing expected in mid-2022"
03/23/2022 6-K Quarterly results
03/15/2022 6-K Quarterly results
03/09/2022 6-K Quarterly results
02/08/2022 6-K Quarterly results
01/28/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Freeline Therapeutics Holdings plc Amended and Restated 2021 Equity Inducement Plan",
"Freeline Therapeutics Holdings plc Amended and Restated 2020 Equity Incentive Plan",
"Freeline Therapeutics Holdings plc Amended and Restated 2020 Share Option Plan"
01/06/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Freeline Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1"
12/13/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Freeline Announces 2022 Corporate Priorities and Guidance"
12/13/2021 6-K Quarterly results
11/17/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Sales Agreement, by and between the Company and Jefferies LLC",
"Opinion of Skadden, Arps, Slate, Meagher & Flom (UK) LLP"
11/09/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Cash Position: Cash and cash equivalents were $136.4 million as of September 30, 2021, as compared to $230.0 million as of December 31, 2020. Based on the Company’s revised operating plan, Freeline expects that its current level of cash and cash equivalents will enable the Company to fund its operating expenses into the first quarter of 2023. The Company continues to review its operations to focus resources on efforts that are expected to return the highest value to its shareholders. • R&D Expenses: Research and development expenses for the nine months ended September 30, 2021 were $70.8 million, as compared to $55.3 million for the same period in 2020. The increase of $15.5 million was driven by increased investment in activities related to the current and proposed clinical trials ..."
08/13/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Press Release dated August 13, 2021, “Freeline Provides Executive Leadership Team Update; Company to Provide Corporate Update and Second Quarter 2021 Financial Results on Monday, August 16th”"
06/29/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy